Background 22 The arsenal in anthelminthic treatment against schistosomiasis is limited and relies almost 23 exclusively on a single drug, praziquantel (PZQ). Thus, resistance to PZQ could constitute a 24 major threat. Even though PZQ is potent in killing adult worms, it has been shown to be limited 25 in its activity against earlier developmental stages. Current in vitro screening strategies for new 26 drugs depend on newly transformed schistosomulae (NTS) for initial hit identification, thereby 27 limiting sensitivity to new compounds predominantly active in later developmental stages. 28 Therefore, the aim of this study was to establish a highly standardized, straightforward and 29 reliable culture method to generate and maintain advanced larval stages in vitro. We present 30 here how this method can be a valuable tool to test drug efficacy at each discrete intermediate 31 larval stage, reducing the reliance on animal use (3Rs).
Briefly, cercariae were incubated 30 min on ice then centrifuged at 1932 x g for 3 min at 4°C. Scoring criteria for the viability score 156 Viability of NTS was scored using an Axiovert10 microscope (Zeiss, Germany). The scoring 9 161 reduced motility, rough outer tegument with some blebs) to 2 (reduced motility or increased 162 uncoordinated activity, slight granularity, intact tegument with slight deformations) and finally 163 3 (regular smooth contractions, no blebs and a smooth outer surface, no granulation with clear 164 view of internal structures). Viability was scored at indicated time points. Since the final score 165 was as an average of all parasites in each well (n=3), the score points were applied in 0.25 steps 166 (S1 Fig) . Growth promotion with human serum 169 Blood sampling of HSe was prepared from blood of consenting healthy volunteers with no 170 previous history of schistosomiasis upon written consent. Fresh blood was left at room 171 temperature for 30 min to clot, then centrifuged at 1845 x g for 20 min and serum was collected 172 and pooled from 6 individuals and stored at -20°C until further use. NTS were incubated (100 173 in 150 µl) in pure HM and DMEM as controls, or with HSe in different concentrations (1-50%) 174 at 37°C for 8 weeks in a 96-well plate. Medium was changed weekly and viability was scored 175 on day 1, 3 and 7 post transformation (p.t.) and then again, every 7 days. Developmental stages 176 were determined via bright field microscopy using an inverted Axiovert 10 microscope (Zeiss). 197 For statistical analysis of the drug treatment experiments, Mann-Whitney U testing was 198 performed to determine statistically significant differences between the DMSO control and the 199 treated groups. The reportable results are shown as a mean ± SD of the viability score points of 200 three pooled independent experiments with three replicates each. Statistical testing was done 201 with IBM SPSS Statistics 24 (IBM). Graphs were generated using the Graphs PRISM 5 202 (GraphPad) was used. To generate and maintain NTS under serum-and cell-free conditions, we cultivated NTS 208 immediately following transformation in different highly standardized and commercially 209 available culture media such as HM, DMEM, RPMI and M199 ( Fig 1A, B) and hardly any observable granularity. Then viability declined slightly (2.0 ± 0.0) due to the 215 death of single NTS and slight internal granulation on day 7 after which the viability stabilized 216 throughout the remainder of the experiment (Fig 1A, B ). In HM, NTS initially scored (2.0 ± 217 0.3) on day 3 p.t., slightly lower compared to those in DMEM. However, from one week p.t.
218
onwards, NTS in HM had already surpassed those kept in DMEM in the viability scoring (2.7 219 ± 0.3) due to the absence of granularity and increase of regular, steady movement. NTS in HM 220 stayed viable throughout the experiment (four weeks) ( Fig 1A, B ). Compared to these two we supplemented HM and DMEM with 20% HSe. In both serum-free controls, we observed a 254 decline in viability after the fourth week of observation (Fig 2A) . In serum-free HM and DMEM 255 controls, only SkS and LuS schistosomulae were observed alongside some dead parasites. In 299 Surprisingly, however, at a concentration of 50% HSe, the survival rate (69.1% or 44.7 ± 10.1 300 dead out of 144.7 ± 21.2 total) as well as viability (2.2 ± 0.6) started to decline around week 8 301 ( Fig 3D, E) . Nevertheless, the final viability score and survival rate was still higher than in the Schistosomes have a complex, multi-stage lifecycle. Even within mammalian hosts, their 330 maturation encompasses well-defined stages. We then were interested to test the different stages 16 331 (SkS, LuS and late LiS) in an in vitro drug testing; we chose drugs with known anti-332 schistosomal properties [24, 28] . We cultured in vitro late LiS (6-week-old schistosomulae) 333 ( Fig 4A, C, E and G), LuS (7-day-old NTS) ( Fig 4B, D, F and H) and SkS (24-hour-old NTS) 334 (S5 Fig A-D) NTS in the presence or absence of different concentrations (100, 10 and 1 µg/ml) 335 of PZQ ( Fig 4A, B and S5 Fig A) OXM (Fig 4C, D and S5 Fig B) , MFQ ( Fig 4E, F and S5 Fig   336 C) or ART ( Fig 4G, H and S5 Fig D) followed by regular viability scorings.
337
PZQ treatment was detrimental to LiS and LuS at all concentrations, which was clearly evident 338 from the drop in viability as soon as 3h a.t. and the death of almost all parasites on day 1 a.t.
339
( Fig 4A, B) , characterized by contracted parasites, damaged tegument and no detectable 340 motility (S6 Fig). No such pronounced effect of PZQ was observed on SkS schistosomulae, 341 however, only high concentrations of PZQ slightly reduced the observed viability starting at 3h 342 a.t., but NTS viability then stabilized for the remaining part of the experiment (S5 Fig A) . In (Fig 5A) . OXM and MFQ both had similar effects on the LiS in high 347 concentrations. In particular, MFQ had a clear and strong anti-schistosomal activity at 100 348 µg/ml. In contrast to MFQ, OXM was also potent at 1 µg/ml. even more so than at 10 µg/ml 349 (Fig 4C, E) . MFQ showed similar activity on the SkS and LuS compared with the LiS (Fig 4E, 
350
F and S5 Fig C) . Overall, OXM was potent in reducing the viability of the parasites in the SkS 351 at all tested concentrations. Even though the LuS was the least susceptible stage to OXM, a 352 reduction in the viability could still be observed which was most prominent at 1 µg/ml (Fig 4C, (Fig 4G, H) , but a slight reduction in viability of the 364 SkS at 100 µg/ml (S5 Fig D) . On day 3 a.t., we could not detect a drop in viability or any 365 morphological changes in any of the tested stages in HSe-supplemented medium (S6 Fig) or in 366 serum-free medium; however, we could detect a clearly schistosomicidal effect at 100µg/ml, 367 with the death following an initial paralysis of the parasites. However, upon addition of the drug 368 to serum free-culture, the previously solved drug precipitated to a small extent ( Fig 5D) . Taken 369 together, we could show the varying stage-dependent activity profiles of selected compounds 370 already known for their anti-schistosomal properties. human blood cells to generate advanced larval and juvenile worm stages [16, 38] . Viability 421 scoring relies on visual assessment of the larvae in culture by bright field microscopy, which 422 still is the gold standard for drug efficacy tests [23, 24] . While the method has its merits, and 423 can be highly effective for dedicated drug efficacy testing, it is very labor intensive. At the same 424 time, microphotographic-based automated analysis [39] using algorithms is complicated by the 425 presence of large numbers of RBCs and/or PBMCs that overlay or colocalize with larvae, 426 making reliable assessment of tegument damage, for example, something for the "trained eye" 427 only. Moreover, the repeated addition of fresh cells from human donors is a factor that is 428 difficult or impossible to fully standardize.
429
In this study, we generated a novel cell-free in vitro assay that allows the development and [40] and additionally, it was shown that S. mansoni has two insulin receptors (SmIR1 and 443 SmIR2), essential for the survival of the pathogen in vitro as well as in vivo [41] . Interestingly, 444 and in contrast to the natural development in vivo, NTS development halted in serum-free media 445 at a stage that, in terms of size and morphology, closely resembles that found in the lung 21 446 vasculature [17] . Considering that the parasite is blood-dwelling, permanently surrounded by 447 the blood components of its typical definitive human host [2, 27, 42] , we were interested to 448 investigate if supplementation with HSe promoted continued NTS development. Indeed, not 449 only did we observe improved overall viability, but also the serum induced concentration- developmental stages in initial hit identification strategies for future drug screenings, making it 462 possible to identify compounds with an activity profile predominantly targeting juvenile or 463 adult worms as is the case for PZQ [43] . Such drugs would probably otherwise be missed.
464
Taken together, we show that in contrast to cercariae that are susceptible to the complement 465 system present in serum [44] , schistosomulae not only tolerate the presence of HSe, but actually 466 require it to progress to late-stage larval stages within their definite host, the human.
467
Another aim of this study was to investigate the suitability of this method to screen compound 468 libraries for schistosomicidal activity against, in particular, advanced stages of S. mansoni in 469 addition to the already often tested early stages [24, 39] . NTS showed comparable stage-specific 470 susceptibility to four drugs known to possess anti-schistosomal properties as seen previously 22 471 with other in vitro assays [16, 24] , confirming the validity of our novel culture method. For 472 example, PZQ, undoubtedly the most important tool to control schistosomiasis in the field, [16, 473 45] was described to act predominantly on juvenile and adult worms [19, 43] , something we 474 could confirm in our novel culture for the corresponding developmental stages of S. mansoni 475 in accordance with previous work [24] . The substantial tegumental damage and anti-476 schistosomal activity in our assay induced by OXM, the drug used against S. mansoni before 477 the discovery of PZQ [46, 47] , was also comparable to that observed by others [16, 24] . 478 Specifically, morphological changes of the tegument as well as schistosomicidal activity more 479 pronounced against LiS and SkS schistosomulae at high concentrations could be observed. The 480 observed increased activity in 1 µg/ml compared with 10 µg/ml surprised us. However, similar 481 observations have been made in previous studies [24] . MFQ is an anti-malarial drug, that was 482 shown to also be active against S. mansoni in vivo and in vitro [48] and is thought to impact 483 heme detoxification as well as glycolysis in the parasite [49] . Interestingly, the stage-dependent 484 activity profile of MFQ is different to that of PZQ and more potently targets the early larval 485 stages than mature worms [25], something we were able to confirm in our novel assay as well.
486
ART is another anti-malarial drug that was shown to act against S. mansoni as well [28] , thought 487 to act via toxication by the hemin byproduct of the parasite's digestion of hemoglobin. Indeed, 488 in absence of a cellular source of hemoglobin, ART seemed to be inactive, supporting the notion 489 that hemin is required for the efficacy of the drug [50]. In the absence of serum during early 490 developmental stages, we found strongly enhanced schistosomicidal activity of MFQ, slightly 491 increased potency of ART, but mostly unchanged activity of PZQ and OXM. Bioavailability of 492 MFQ is known to be strongly dependent on binding to plasma proteins (which can be as high 493 as 98% [51]) and for ART plasma-binding lies between 92-98%, in line with our observed 494 increase in activity in serum-free cultures [52] . On the other hand, PZQ binds to a lesser extent 495 to plasma proteins (~80%) in concentrations of 10-100 µg/ml and in vitro as low as 50% [53] , 496 something that is also reflected in the limited increase in toxicity we observed in non-serum 23 497 supplemented cultures. Importantly, our assay allows researchers to continually observe 498 toxicity effects and inhibition of maturation from early developmental stages towards mature 499 larval and juvenile worms in settings ranging from compound or drug testing, but also to screen 500 for natural factors from non-permissive hosts or, reversely, identify growth-promoting 501 compounds from the host-adapted, parasite friendly environment.
502
Taken together, juvenile worms generated in our cell-free assay behave and respond similarly 503 to ex vivo harvested worms from infected laboratory animals in drug screening assays [24] .
504
However, in contrast to the limited numbers of labor-intensive, in vivo generated parasites, our 505 in vitro culture method allows for the generation of good numbers of parasites at all stages of 506 development for large-scale drug screening assays. Also, the independency of host blood cells 507 facilitates automated assessment of larval viability in large-scale assays, due to a lack of visual 508 interference by host cells. In addition, the high level of standardization and minimization of 509 host-to-host variability in the assay, will allow researchers to use it to investigate and identify 510 components within HSe that are exploited by the parasite for its development in the dominant 511 definite human host and define mechanisms that underlie the host-specificity of this parasite.
512
Ultimately, such understanding will pave the way for the identification of new drug and 513 vaccination targets. LiS (early LiS (5% and 10%) and late liver stage (20% and 50%)). 
